PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 2007 September; 78(9): 970–974.
Published online 2007 March 2. doi:  10.1136/jnnp.2006.107243
PMCID: PMC2117888

Detection of HP10 antigen in serum for diagnosis and follow‐up of subarachnoidal and intraventricular human neurocysticercosis

Abstract

Introduction

Neurocysticercosis (NC), a parasitic disease caused by Taenia solium, may be either asymptomatic or show a mild to severe clinical picture with intracranial hypertension. The most severe form of the disease is caused when viable cysticerci are localised in the ventricles or in subarachnoidal cisterns at the base of the skull. Detection of the secreted metacestode antigen HP10 in cerebrospinal fluid is a sensitive and specific method for the diagnosis of these severe NC cases.

Objective and methods

To evaluate the validity of HP10 antigen detection ELISA when applied to serum, using paired serum and cerebrospinal fluid samples from 116 radiologically and clinically characterised NC patients.

Results

The HP10 antigen assay exhibited a similarly high sensitivity in identifying severe NC cases from sera (84.8%) and CSF (91.3%). In contrast, HP10 antigen was rarely detected in asymptomatic or mild NC cases (3 of 57). Importantly, the HP10 antigen assay applied to serum showed high specificity (94%) when used in 126 serum samples of non‐NC subjects from an endemic community with a confirmed coproparasitological diagnosis of intestinal parasitic infections. Finally, the HP10 assay also proved to be of value in the follow‐up of treated patients.

Conclusion

This study confirms that detection of the metacestode HP10 antigen in serum is a useful tool for diagnosis and follow‐up of patients with severe forms of NC treated with cysticidal drugs.

Taenia solium is still endemic in most countries in Latin America, Asia and Africa. When the larva is localised in the central nervous system (CNS) it causes neurocysticercosis (NC), a parasitic infection that affects approximately 10% of the inhabitants of rural communities of endemic countries.1,2,3 The clinical presentation of NC can vary from an asymptomatic to a deadly disease.4 One of the factors critically involved in this clinical heterogeneity is the parasite location in the CNS. Thus when the parasite is located in the parenchyma or in the subarachnoidal (SA) space of the sulci, most patients exhibit a benign clinical presentation. In contrast, when the parasite is located in the SA space at the base of the skull or in the ventricles, a severe clinical picture is presented, frequently accompanied by intracranial hypertension. The latter localisation commonly requires surgical intervention (ventriculoperitoneal shunt), and the parasites are usually less sensitive to cysticidal treatment.5

As diagnosis and follow‐up of NC still require costly and not always accessible radiological studies, multiple attempts have been made to develop sensitive and specific immunodiagnostic tools.6,7,8,9 Of particular interest is the detection of secreted parasite antigens, as these only identify viable parasites.10 The most extensively tested antigen has been HP10, which includes in its structure epitopes shared by different cestodes (eg, Taenia saginata, Taenia solium and Taenia crassiceps).10,11,12 Recent reports have shown that HP10 detection is an indicator of the presence of vesicular cysticerci located in the SA space at the base of the skull or in the ventricles, the most severe forms of NC. HP10 detection in serum has also been reported to be useful as an indicator of the presence of vesicular parasites in hydrocephalus secondary to NC.13 Also, the level of HP10 antigen significantly decreases after effective cysticidal treatment, thereby reducing the number of required imaging studies.13,14,15,16

This study was designed to evaluate the specificity and sensitivity of the HP10 assay in sera and compare it with antibody and HP10 detection in CSF. Paired CSF and sera samples from the same NC patients were used for these purposes. The specificity of the assay was determined based on the levels observed in the sera of inhabitants without cysticercosis from a T solium endemic rural community.

Materials and methods

Paired CSF and serum samples from hospital patients

CSF and sera were simultaneously collected from 116 NC patients at the Instituto Nacional de Neurología y Neurocirugía, Mexico City. These patients represent almost all of the subjects with NC that required lumbar puncture over a 12 month period for their diagnosis and/or follow‐up. In 13 of these patients, paired CSF and serum samples were obtained before and after treatment (cysticidal drugs and corticosteroids or surgical treatment). In all cases, diagnosis was based on: clinical manifestations (presence of seizures, focal deficit and intracranial hypertension) and imaging studies (image compatible with the presence of vesicular, colloidal or calcified cysticerci). The following information was collected for each NC case from the radiological studies (CT and MRI): state of the cysticerci (vesicular, colloidal or calcified) and CNS location (SA space at the base of the skull, convexity SA space, parenchyma or ventricles).

Patients were informed that sera and CSF samples obtained during their hospital studies would be used for this work and gave their informed consent.

This study had a double blind design. Neither the neurologists nor the radiologists knew the results of the HP10 test and the laboratory technicians did not know the clinical diagnosis of the neurological patients.

Serum samples from inhabitants of endemic community and from subjects with hepatic abscesses

To evaluate the specificity of the HP10 antigen detection assay, the HP10 level was determined in 126 inhabitants from a highly endemic rural community previously studied for epidemiological purposes.2 All of these subjects were examined for NC by CT, and in 77, coproparasitoscopic examinations were also performed in serial faecal samples, as described elsewhere.2 HP10 antigen was also measured in 25 patients with hepatic abscesses (10 pyogenic and 15 amoebic).

Detection of specific antibodies

Anticysticercal antibodies were determined by ELISA using cysticercal fluid as a source of antigens following the procedure previously described.2 Samples were run in duplicate and a sample was considered positive if the mean optical density (OD) value was higher than the cut off value, which was calculated based on the mean of the OD plus 2 SD of 82 CSF (0.20) and 41 serum (0.28) samples from non‐NC controls. The reproducibility of the assay was assessed based on the coefficient of variation (CV) defined as ((SD/mean)×100). The intra‐assay CV was 2.6% and the interassay was 6.9%.

Detection of HP10 antigen

HP10 antigen was detected by Ag‐ELISA as described previously.10,16 Samples were run in duplicate.

Briefly, Immulon I plates (Nunc, Rochester, New York, USA) were coated with monoclonal antibody HP10 (100 μl at 10 μg/ml in 0.07 M NaCl buffered with 0.1 M borate, pH 8.2) and left overnight at 4°C. The plates were washed four times with 200 μl/well of wash solution (0.9% w/v NaCl containing 0.05% v/v Tween 20). The plates were blocked using 200 μl diluent (phosphate buffered saline containing bovine serum albumin 1.0% w/v and 0.05% v/v Tween 20) and left for 60 min at room temperature before being washed in a similar way. Undiluted CSF or serum samples (100 μl/well) were added and incubated for 30 min at 37°C. Bound HP10 parasite antigen was detected using biotinylated monoclonal antibody HP10 (1:4000 in diluent, for 30 min at 37°C), horseradish peroxidase conjugated streptavidin (Zymed, San Francisco, California, USA) (1:4000 in diluent, 30 min at 37°C) and tetramethylbenzidine (Zymed) as substrate. The colour reaction was allowed to proceed for 30 min at 37°C in the dark and was stopped by adding 100 μl 0.2 M H2SO4 (Baker, Estado de Mexico, Mexico). OD (450 nM) was determined in an ELISA processor (Versamax microplate reader; Molecular Devisable, Sunnyvale, California, USA).

A sample was considered positive if the mean OD value was higher than the cut off value, which was calculated based on the mean of the OD plus 2 SD of 82 CSF (0.26) and 41 sera (0.20) samples from non‐NC controls. The assay exhibited high reproducibility (intra‐assay CV = 2.9%; interassay CV = 13%).

Statistical analysis

Data were processed in Excel 7.0 (Microsoft) and SPSS 10.0 for Windows. Parametric descriptions (mean and SD) were calculated. Univariate analysis of the data (Pearson's ×2 test with Yates' correction or Fisher's test when appropriate) was used to identify the differences in absorbance values between groups. A p value [less-than-or-eq, slant]0.05 was considered significant. Differences between mean ODs were evaluated by Tukey's post hoc test. Kappa coefficient (κ) was calculated to evaluate the qualitative concordances between HP10 results in CSF and sera. This coefficient varied between −1 and +1. The closer the value to 1, the stronger the concordance.17

Results

HP10 antigen is detected in serum and CSF in most of the severe NC cases

Table 11 shows that HP10 was detected in 84.8% (39/46) of serum and 91.3% (42/46) of CSF samples in NC patients with vesicular cysticerci in the SA space of the base or in the ventricles, the most severe forms of the disease. Interestingly, 96.5% and 100% of these NC cases also exhibited increased levels of specific antibodies in serum and CSF, respectively. No significant differences were found in the sensitivity of HP10 and antibody detection in these severe NC cases (p = 0.2).

Table thumbnail
Table 1 Sensitivity (%) of antibody and HP10 detection in sera and CSF of 121 neurological patients

The HP10 antigen was not detected in serum or CSF samples from the six patients with less severe disease with parenchymal cysticerci, and was identified in only three sera and two CSF samples from treated patients in which no cysticerci were found by radiological studies. In contrast, antibodies were detected in 80% of the parenchymal NC cases and in 40.4% and 68% in sera and CSF, respectively, of patients with damaged cysticerci.

The level of HP10 antigen significantly correlated between paired serum and CSF samples (fig 11).). Considering the vesicular NC cases with parasites located in the SA space of the base or in the ventricles, 39 of 46 cases were HP10 positive in sera and CSF and four were HP10 negative in both samples (κ = 0.69; p<0.0001). The six vesicular NC cases with cysticerci in the parenchyma were negative in both samples, and in 48 of the 51 cases with damaged parasites, HP10 levels were negative (n = 47) or positive in both (n = 1) (κ = 0.37, p = 0.007). However, most of the patients showed higher levels of HP10 antigen in the CSF, with only a few cases where the reverse was observed.

figure jn107243.f1
Figure 1 Scatterplot indicating the ELISA optical density (OD) values obtained in the HP10 antigen ELISA using serum and CSF from the 116 patients with neurocysticercosis involved in the study (Pearson correlation coefficient r = 0.77, ...

Levels of HP10 in sera and CSF did not correlate with the level of CSF inflammation. In addition, no significant differences were found in the mean number of cells in CSF between NC patients who were HP10 positive or negative, in CSF or in sera.

Levels of HP10 antigen in the three groups of NC patients (vesicular in SA base or ventricles, parenchymal vesicular and inactive) are illustrated in fig 22.. There was a marked difference in the levels of HP10 between the group of patients with severe NC (group 1) and the group with less severe NC (groups 2 and 3). In contrast, there was less variation in the levels of antibody detected in the three different clinical groups. Thus, in CSF, the difference was 1.86 (1.4–2.3) for HP10 detection and 0.59 (0.09–1.08) for antibody detection. Similarly, in serum, the values were 1.24 (0.8–1.7) for HP10 detection and 0.7 (0.2–1.2) for antibody detection.

figure jn107243.f2
Figure 2 Levels of HP10 parasite antigen and anticysticercal antibodies in the serum and CSF in the three groups of patients with neurocysticercosis (NC). VSAb/Ve, patients with vesicular NC with the cysts located in the subarachnoid space at ...

High specificity of HP10 detection

To test the specificity of the assay, HP10 levels were determined in a total of 126 inhabitants of a rural community endemic for cysticercosis and in 25 subjects with hepatic abscess (pyogenic or amoebic). An increased level of HP10 was found in only nine subjects (94% specificity). Coproparasitological analyses were also performed on 77 of the patients, and at least one infectious agent was detected in 36. Increased HP10 levels were not associated with the presence of calcified cysticerci in the CNS (p = 0.54) or any of the following infectious agents: Entamoeba coli, p = 0.34; Giardia lamblia, p = 0.45 or Ascaris lumbricoides, p = 1). An apparently significant association was observed with Entamoeba histolytica (3 of 6 HP10 positive subjects were infected by this parasite vs only 6 of 71 HP10 negative subjects, p = 0.02). The relevance of this association is doubtful, however, as increased levels of HP10 were not found in a total of 15 additional patients with confirmed amoebic hepatic abscess (p = 0.5).

HP10 antigen detection in sera: a useful tool for decision making in NC treatment

In 13 NC patients, the viability status of the cysticerci after specific treatment could not be determined by radiological studies; 90% of these patients still had antibodies in sera and CSF. However, HP10 was detected in sera in only four individuals, and in CSF in eight.

HP10 antigen detection in sera: a useful tool for the follow‐up of severe NC cases

In 13 NC patients, HP10 levels were determined in CSF and serum before and after specific treatment. After treatment, the parasites disappeared or became calcified according to radiological studies in the first four patients. Table 22 shows that, in these four patients, HP10 levels dropped after treatment. In contrast, in the other nine patients in whom parasites remained vesicular, HP10 levels continued to be elevated.

Table thumbnail
Table 2 Levels of HP10 antigen in CSF and serum samples taken before and after cysticidal treatment from 13 patients diagnosed with vesicular neurocysticercosis in the subarachnoidal space at the base of the brain or in the ventricles

Discussion

In a previous study it was demonstrated that the secreted metacestode HP10 antigen level in CSF is a highly predictive factor that indicates the presence of vesicular cysticerci in the ventricles or SA space at the base of the skull.18 As the collection of CSF samples is an invasive procedure, we examined the possibility of NC diagnosis via serum HP10 detection. Using a group of 116 NC patients included over a 12 month period, we demonstrated that the HP10 antigen level in serum is an indicator of NC and is as sensitive and specific as it is in CSF. A high correlation (r = 0.77) was observed between levels of antigen detected in each compartment. Not surprisingly, in most cases, higher levels of HP10 antigen were found in CSF than in serum. The possibility that vesicular cysticerci localised outside of the CNS could contribute to the increased levels of antigen in serum cannot be discarded.19 However, the high specificity (94%) found in this study using sera from inhabitants of a community highly endemic for T solium suggests that cases of extra‐CNS cysticercosis with or without cerebral involvement are very rare. This possibility is supported by the almost total absence of subcutaneous nodules found in a screened population of thousands of subjects in a zone of high NC prevalence in Ecuador.20 Thus detection of serum HP10 antigen as a possible indicator of ventricular or subarachnoidal NC could be particularly useful as a first diagnostic tool in endemic countries where the necessary imaging facilities are not available. Clearly, subsequent confirmation by imaging would then be carried out.

The effectiveness of serum HP10 antigen detection for the diagnosis of severe NC cases could be extremely useful, not only because testing serum antigen levels is a more simple intervention but also because: (a) in cases of severe NC usually accompanied by intracranial hypertension, CSF retrieval is contraindicated; (b) it is a non‐invasive and useful method to support the diagnosis of severe NC when radiological studies are not satisfactory; and (c) it is a useful method for the follow‐up of vesicular SA base or ventricle NC confirmed patients.

With respect to the antibody response, the most obvious correlation was that a high proportion of NC patients with vesicular cysticerci in the SA space or in the ventricles exhibited increased antibody levels. However, antibody levels remain increased several months after parasite calcification,2 and they are present in NC patients, regardless of parasite location or severity. Consequently, antibody detection, although very useful for epidemiological purposes, is not a reliable indicator of active NC.

In summary, this study of an extensive and heterogeneous group of patients has demonstrated the usefulness of serum HP10 detection for the diagnosis of NC. The usefulness of the HP10 antigen for the follow‐up of treated patients with cysticerci located in ventricles or in the subarachnoidal cisterns at the base of the skull was also clearly established. These findings justify the development of a lateral flow immunochromatographic HP10 antigen detection assay which may be used as a screening and follow‐up assay in epidemiological studies, doctor's offices and clinical laboratories.

Acknowledgements

We thank Dr Carlos Marquez and Mercedes Baca for clinical and technical assistance. The authors thank Dr Cecilia Jiménez for providing the sera from patients with hepatic abscess. Isabel Pérez Montfort corrected the English version of the manuscript. This study was supported by Silanes Laboratory, SEP‐CONACYT (46953‐M), the Howard Hughes Medical Institute (55000643), the Universidad Nacional Autónoma de México and the Instituto Nacional de Neurología y Neurocirugía, México.

Abbreviations

CNS - central nervous system

NC - neurocysticercosis

OD - optical density

SA - subarachnoidal

Footnotes

Competing interests: None.

References

1. Sanchez A L, Ljungstrom I, Medina M T. Diagnosis of human neurocysticercosis in endemic countries: a clinical study in Honduras. Parasitol Int 1999. 181–89.89 [PubMed]
2. Fleury A, Gomez T, Alvarez I. et al High prevalence of calcified silent neurocysticercosis in a rural village of Mexico. Neuroepidemiology 2003. 22139–145.145 [PubMed]
3. Fleury A, Morales J, Bobes R J. et al An epidemiological study of familial neurocysticercosis in an endemic Mexican community. Trans R Soc Trop Med Hyg 2006. 100551–558.558 [PubMed]
4. Fleury A, Dessein A, Preux P M. et al Symptomatic human neurocysticercosis: age, sex and exposure factors relating with disease heterogeneity. J Neurol 2004. 251830–837.837 [PubMed]
5. Gongora‐Rivera F, Soto‐Hernandez J L, Gonzalez Esquivel D. et al Albendazole trial at 15 or 30 mg/kg/day for subarachnoid and intraventricular cysticercosis. Neurology 2006. 66436–438.438 [PubMed]
6. Correa D, Sandoval M A, Harrison L J. et al Human neurocysticercosis: comparison of enzyme immunoassay capture techniques based on monoclonal and polyclonal antibodies for the detection of parasite products in cerebrospinal fluid. Trans R Soc Trop Med Hyg 1989. 83814–816.816 [PubMed]
7. Tsang V C, Brand J A, Boyer A E. An enzyme‐linked immunoelectrotransfer blot assay and glycoprotein antigens for diagnosing human cysticercosis (Taenia solium). J Infect Dis 1989. 15950–59.59 [PubMed]
8. Ramos‐Kuri M, Montoya R M, Padilla A. et al Immunodiagnosis of neurocysticercosis. Disappointing performance of serology (enzyme‐linked immunosorbent assay) in an unbiased sample of neurological patients. Arch Neurol 1992. 49633–636.636 [PubMed]
9. Larralde C, Sotelo J, Montoya R M. et al Immunodiagnosis of human cysticercosis in cerebrospinal fluid. Antigens from murine Taenia crassiceps cysticerci effectively substitute those from porcine Taenia solium. Arch Pathol Lab Med 1990. 114926–928.928 [PubMed]
10. Harrison L J, Joshua G W, Wright S H. et al Specific detection of circulating surface/secreted glycoproteins of viable cysticerci in Taenia saginata cysticercosis. Parasite Immunol 1989. 11351–370.370 [PubMed]
11. Harrison L J, Garate T, Bryce D M. et al Ag‐ELISA and PCR for monitoring the vaccination of cattle against Taenia saginata cysticercosis using an oncospheral adhesion protein (HP6) with surface and secreted localization. Trop Anim Health Prod 2005. 37103–120.120 [PubMed]
12. Sciutto E, Hernandez M, Garcia G. et al Diagnosis of porcine cysticercosis: a comparative study of serological tests for detection of circulating antibody and viable parasites. Vet Parasitol 1998. 78185–194.194 [PubMed]
13. Garcia H H, Gonzalez A E, Gilman R H. et al Circulating parasite antigen in patients with hydrocephalus secondary to neurocysticercosis. Am J Trop Med Hyg 2002. 66427–430.430 [PubMed]
14. Garcia H H, Harrison L J, Parkhouse R M. et al A specific antigen‐detection ELISA for the diagnosis of human neurocysticercosis. The Cysticercosis Working Group in Peru. Trans R Soc Trop Med Hyg 1998. 92411–414.414 [PubMed]
15. Garcia H H, Parkhouse R M, Gilman R H. et al Serum antigen detection in the diagnosis, treatment, and follow‐up of neurocysticercosis patients. Trans R Soc Trop Med Hyg 2000. 94673–676.676 [PubMed]
16. Fleury A, Hernandez M, Fragoso G. et al Detection of secreted cysticercal antigen: a useful tool in the diagnosis of inflammatory neurocysticercosis. Trans R Soc Trop Med Hyg 2003. 97542–546.546 [PubMed]
17. Bernard P M, Lapointe C. Mesures d'accord. In: Mesures statistiques en épidémiologie. Sainte‐Foy, Québec: Presses de l'Université du Québec 1995. 131–143.143
18. Bobes R J, Hernández M, Márquez C. et al Subarachnoidal and intraventricular human neurocysticercosis: application of an antigen detection assay for the diagnosis and follow‐up. Trop Med Int Health 2006. 11943–950.950 [PubMed]
19. Bustos J A, Garcia H H, Dorregaray R. et al Detection of muscle calcifications by thigh CT scan in neurocysticercosis patients. Trans R Soc Trop Med Hyg 2005. 99775–779.779 [PubMed]
20. Cruz I, Cruz M E, Teran W. et al Human subcutaneous Taenia solium cysticercosis in an Andean population with neurocysticercosis. Am J Trop Med Hyg 1994. 51405–407.407 [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Group